Allergan PLC (ACT, Financial), Celgene Corp. (CELG, Financial), WPP PLC (WPP, Financial) and Invesco Ltd. (IVZ, Financial) have declined to their three-year lows.
Allergan PLC (ACT, Financial) declined to $24.96
The prices of Allergan PLC (ACT, Financial) shares have declined to $24.96, which is only 2.9% above the 3-year low of $24.23.
Allergan PLC is an Irish international pharmaceutical company that produces both branded and generic drugs. The company also performs pharmaceutical research and development. The company’s key products include Actonel, Acuvail, Aczone, Lumigan, Namenda, Ozurdex and Rapaflo.
Allergan PLC has a market cap of $117.25 billion; its shares were traded around $24.96 with a P/E ratio of 24.22 and P/S ratio of 3.35.
On Oct. 30 Allergan PLC reported third quarter 2018 results. GAAP loss per share for the quarter was 11 cents, while GAAP operating income was $257.5 million. Net revenue for the quarter was $3.91 billion, compared to $4.03 billion during the same quarter prior year.
Celgene Corp. (CELG, Financial) declined to $69.65
The prices of Celgene Corp. (CELG, Financial) shares have declined to $69.65, which is only 1.1% above the 3-year low of $68.91.
Celgene Corp. is an American biotechnology company that researches, develops, and commercializes treatments relating to cancer and inflammatory disorders. The company’s major product is Revlimid, which in combination with dexamethasone treats multiple myeloma in patients. Revlimid is sold through proprietary risk management distribution programs to ensure safe and appropriate use.
Celgene Corp. has a market cap of $48.46 billion; its shares were traded around $69.65 with a P/E ratio of 17.73 and P/S ratio of 3.56. Celgene Corp. had an annual average earnings growth of 21.40% over the past 5 years.
On Oct. 25 Celgene Corp. reported third quarter 2018 financial results. Net product sales for the quarter was $3.89 billion, an 18% increase from the same quarter prior year. Net revenue for the quarter was $3.89 billion, also an 18% increase compared to $3.29 billion during the same quarter prior year. GAAP diluted earnings per share for the quarter was $1.50, compared to diluted EPS of $1.21 during the same quarter prior year.
WPP PLC (WPP, Financial) declined to $55.13
The prices of WPP PLC (WPP, Financial) shares have declined to $55.13, which is only 1.6% above the 3-year low of $54.24.
WPP PLC is a British international advertising and public relations company. The company owns a variety of advertising, public relations and market research networks, including IMRB, Millward Brown, Grey and TNS. The company is a component of the FTSE 100 Index and has listings in both the NASDAQ and LSE.
WPP PLC has a market cap of $14.02 billion; its shares were traded around $55.13 with a P/E ratio of 5.67 and P/S ratio of 0.71. The trailing 12-month dividend yield of WPP PLC stocks is 7.39%. The forward dividend yield of WPP PLC stocks is 7.33%. WPP PLC had an annual average earnings growth of 7.80% over the past 10 years.
On Oct. 25 WPP PLC reported third quarter 2018 financial results. Revenue decreased by 0.8% to £3.758 billion from £3.788 billion from the same quarter prior year. Third quarter constant currency revenue increased by 1.2%.
Invesco Ltd. (IVZ, Financial) declined to $20.07
The prices of Invesco Ltd. (IVZ, Financial) shares have declined to $20.07, which is only 3.9% above the 3-year low of $19.28.
Invesco Ltd. has a market cap of $9.92 billion; its shares were traded around $24.14 with a P/E ratio of 8.47 and P/S ratio of 1.79. The trailing 12-month dividend yield of Invesco Ltd. stocks is 4.89%. The forward dividend yield of Invesco Ltd. stocks is 4.94%. Invesco Ltd. had an annual average earnings growth of 8.40% over the past 10 years.
Invesco Ltd. has a market cap of $8.25 billion; its shares were traded around $20.07 with a P/E ratio of 7.05 and P/S ratio of 1.45. The trailing 12-month dividend yield of Invesco Ltd. stocks is 5.93%. The forward dividend yield of Invesco Ltd. stocks is 5.98%. Invesco Ltd. had an annual average earnings growth of 8.40% over the past 10 years.
On Oct. 18 Invesco Ltd. announced that it has entered into a definitive agreement with Massachusetts Mutual Life Insurance Company to acquire MassMutual asset management affiliate Oppenheimer Funds Inc. MassMutual and Oppenheimer Funds employees will receive a combination of common and preferred equity consideration and MassMutual will become a significant shareholder in Invesco, with approximately a 15.5% stake in the company.
Disclosure: I do not own stock in any of the companies mentioned in the article.
